Regado Biosciences Announces $20 Million Private Placement

          Regado Biosciences Announces $20 Million Private Placement

PR Newswire

BASKING RIDGE, N.J., Jan. 31, 2014

BASKING RIDGE, N.J., Jan. 31, 2014 /PRNewswire/ -- Regado Biosciences, Inc.
(Nasdaq: RGDO), a biopharmaceutical company focused on the late-stage clinical
development of its first-in-class, actively controllable antithrombotic drug
system, REG1, today announced that it has entered into a definitive agreement
to sell $20 million of its common stock in a private placement to new and
existing investors. Under the agreement, the investors will purchase an
aggregate of 4 million shares of common stock at a purchase price of $5.00 per
share. The net proceeds of the offering are expected to be used for general
corporate and working capital purposes, including the ongoing Phase 3
REGULATE-PCI clinical trial. The company believes that the expected net
proceeds of this offering, together with its existing working capital, will be
sufficient to fund the REGULATE-PCI trial through the second interim analysis,
which is expected to occur by the end of the third quarter of 2014.

Cowen and Company acted as the lead placement agent for the offering, and BMO
Capital Markets acted as co-placement agent. The offering is expected to close
on Feb. 5, 2014, subject to customary closing conditions.

The common stock being sold in the offering has not been registered under the
Securities Act of 1933, as amended (the Act), or state securities laws, and
may not be offered or sold in the United States absent registration under the
Act or an applicable exemption from such registration requirements.

This press release shall not constitute an offer to sell or the solicitation
of an offer to buy, nor shall there be any sale of these securities in any
state or jurisdiction in which such offer, solicitation or sale would be
unlawful prior to registration or qualification under the securities laws of
any such state or jurisdiction.

Regado Biosciences, Inc., is a biopharmaceutical company focused on the
development of novel, first-in-class, actively controllable antithrombotic
drug systems for acute and sub-acute cardiovascular indications.Regado is
pioneering the development of two-component drug systems consisting of a
therapeutic aptamer and its specific active control agent. The company's lead
product candidate, REG1, is a two-component system consisting of pegnivacogin,
an anticoagulant aptamer specifically targeting coagulation Factor IXa, and
its complementary oligonucleotide active control agent, anivamersen.REG1 is
currently being evaluated in the REGULATE-PCI trial, a worldwide Phase 3 study
enrolling 13,200 patients with acute coronary syndromes (ACS) undergoing
percutaneous coronary intervention (PCI), a hospital-based procedure used to
mechanically open or widen obstructed coronary arteries.Regado's actively
controllable product candidates have the potential to improve patient
outcomes, enhance the patient experience and reduce overall treatment
costs.More information can be found

For more information on REGULATE-PCI, please visit:

Forward-Looking Statements:
This press release contains forward-looking statements within the meaning of
the Private Securities Litigation Reform Act of 1995. Forward-looking
statements reflect management's current expectations, as of the date of this
press release, and involve certain risks and uncertainties. Forward-looking
statements include statements herein with respect to the successful completion
of the offering described above, the timing of the REGULATE-PCI trial, and the
Company's ability to achieve the second interim analysis in the REGULATE-PCI
trial with the proceeds of the offering and the Company's existing working
capital. The Company's actual results could differ materially from those
anticipated in these forward-looking statements as a result of various
factors. Factors that could cause future results to materially differ from
those projected in forward-looking statements include the "Risk Factors"
described in the Company's Quarterly Report on Form 10-Q filed with the
Securities and Exchange Commission on Nov. 8, 2013, and in the Company's other
periodic filings with the SEC. All forward-looking statements are expressly
qualified in their entirety by this cautionary notice. You are cautioned not
to place undue reliance on any forward-looking statements, which speak only as
of the date of this release. The Company has no obligation, and expressly
disclaim any obligation, to update, revise or correct any of the
forward-looking statements, whether as a result of new information, future
events or otherwise.

Media Contacts:

David Schull or Lena Evans
Russo Partners

Investor Relations Contacts:

Tricia Truehart or Chelsea Wheeler
Trout Group

SOURCE Regado Biosciences, Inc.

Press spacebar to pause and continue. Press esc to stop.